Inhibrx says combo therapy shrank more tumors than Merck's Keytruda alone

San Diego-based biotech Inhibrx is claiming that it outperformed Merck’s Keytruda in a difficult-to-treat cancer. The combination of Keytruda and Inhibrx’s experimental drug INBRX-106 shrank more tumors than Keytruda alone in patients with metastatic head ...